CovidChloroV1, Main, Exploration, bibRecord, 001612

Chloroquine and its derivatives in the management of COVID-19: A scoping review

Identifieur interne : 001612 ( Main/Exploration ); précédent : 001611; suivant : 001613

Chloroquine and its derivatives in the management of COVID-19: A scoping review

Auteurs : Juan Pimentel [Colombie] ; Neil Andersson [Mexique]

Source :

Biomedica : revista del Instituto Nacional de Salud [ 2590-7379 ] ; 2020.

RBID : pubmed:33152192

Descripteurs français

KwdFr :
- Antiviraux (effets indésirables), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (physiologie), Chloroquine (effets indésirables), Chloroquine (pharmacologie), Chloroquine (usage thérapeutique), Enregistrements (MeSH), Essais cliniques comme sujet (MeSH), Essais cliniques à usage compassionnel (MeSH), Essais contrôlés randomisés comme sujet (MeSH), Humains (MeSH), Hydroxychloroquine (effets indésirables), Hydroxychloroquine (pharmacologie), Hydroxychloroquine (usage thérapeutique), Infections à coronavirus (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Repositionnement des médicaments (MeSH), Réplication virale (effets des médicaments et des substances chimiques), Résultat thérapeutique (MeSH), Études multicentriques comme sujet (MeSH).
MESH :
- effets des médicaments et des substances chimiques : Betacoronavirus, Réplication virale.
- effets indésirables : Antiviraux, Chloroquine, Hydroxychloroquine.
- pharmacologie : Antiviraux, Chloroquine, Hydroxychloroquine.
- physiologie : Betacoronavirus.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux, Chloroquine, Hydroxychloroquine.
- Enregistrements, Essais cliniques comme sujet, Essais cliniques à usage compassionnel, Essais contrôlés randomisés comme sujet, Humains, Pandémies, Repositionnement des médicaments, Résultat thérapeutique, Études multicentriques comme sujet.

English descriptors

KwdEn :
- Antiviral Agents (adverse effects), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (physiology), COVID-19 (MeSH), Chloroquine (adverse effects), Chloroquine (pharmacology), Chloroquine (therapeutic use), Clinical Trials as Topic (MeSH), Compassionate Use Trials (MeSH), Coronavirus Infections (drug therapy), Cytokine Release Syndrome (drug therapy), Drug Repositioning (MeSH), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (pharmacology), Hydroxychloroquine (therapeutic use), Multicenter Studies as Topic (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Randomized Controlled Trials as Topic (MeSH), Registries (MeSH), SARS-CoV-2 (MeSH), Treatment Outcome (MeSH), Virus Replication (drug effects).
MESH :
- chemical , adverse effects : Antiviral Agents, Chloroquine, Hydroxychloroquine.
- chemical , pharmacology : Antiviral Agents, Chloroquine, Hydroxychloroquine.
- chemical , therapeutic use : Antiviral Agents, Chloroquine, Hydroxychloroquine.
- drug effects : Betacoronavirus, Virus Replication.
- drug therapy : Coronavirus Infections, Cytokine Release Syndrome, Pneumonia, Viral.
- physiology : Betacoronavirus.
- COVID-19, Clinical Trials as Topic, Compassionate Use Trials, Drug Repositioning, Humans, Multicenter Studies as Topic, Pandemics, Randomized Controlled Trials as Topic, Registries, SARS-CoV-2, Treatment Outcome.

Abstract

Introduction: Recently, researchers from China and France reported on the effectiveness of chloroquine and hydroxychloroquine for the inhibition of SARS-CoV-2 viral replication in vitro. Timely dissemination of scientific information is key in times of pandemic. A systematic review of the effect and safety of these drugs on COVID-19 is urgently needed. Objective: To map published studies until March 25, 2020, on the use of chloroquine and its derivates in patients with COVID-19. Materials and methods: We searched on PubMed, Embase, Lilacs, and 15 registries from the World Health Organization’s International Clinical Trials Registry Platform for theoretical and empirical research in English, Spanish, Italian, French, or Portuguese until March 25, 2020, and made a narrative synthesis of the results. Results: We included 19 records and 24 trial registries (n=43) including 18,059 patients. China registered 66% (16/24) of the trials. Nine trials evaluate chloroquine exclusively and eight hydroxychloroquine. The records are comments (n=9), in vitro studies (n=3), narrative reviews (n=2), clinical guidelines (n=2), as well as a systematic review, an expert consensus, and a clinical trial. Conclusions: One small (n=26), non-randomized, and flawed clinical trial supports hydroxychloroquine use in patients with COVID-19. There is an urgent need for more clinical trial results to determine the effect and safety of chloroquine and hydroxychloroquine on COVID-19.

DOI: 10.7705/biomedica.5478
PubMed: 33152192
PubMed Central: PMC7676841

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000889
to stream Main, to step Curation: 000889

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chloroquine and its derivatives in the management of COVID-19: A scoping review</title>
<author><name sortKey="Pimentel, Juan" sort="Pimentel, Juan" uniqKey="Pimentel J" first="Juan" last="Pimentel">Juan Pimentel</name>
<affiliation wicri:level="4"><nlm:affiliation>Community Information and Epidemiological Technologies - Participatory Research at McGill, CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Canada; Facultad de Medicina, Universidad de La Sabana, Chía, Colombia; Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, D.C., Colombia. juan.pimentel@mail.mcgill.ca.</nlm:affiliation>
<country xml:lang="fr">Colombie</country>
<wicri:regionArea>Community Information and Epidemiological Technologies - Participatory Research at McGill, CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Canada; Facultad de Medicina, Universidad de La Sabana, Chía, Colombia; Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, D.C.</wicri:regionArea>
<orgName type="university">Université McGill</orgName>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Andersson, Neil" sort="Andersson, Neil" uniqKey="Andersson N" first="Neil" last="Andersson">Neil Andersson</name>
<affiliation wicri:level="4"><nlm:affiliation>Community Information and Epidemiological Technologies - Participatory Research at McGill, CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Canada; Centro de Investigación de Enfermedades Tropicales, Universidad Autónoma de Guerrero, Acapulco, México. neil.andersson@mcgill.ca.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Mexique</country>
<wicri:regionArea>Community Information and Epidemiological Technologies - Participatory Research at McGill, CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Canada; Centro de Investigación de Enfermedades Tropicales, Universidad Autónoma de Guerrero, Acapulco</wicri:regionArea>
<orgName type="university">Université McGill</orgName>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33152192</idno>
<idno type="pmid">33152192</idno>
<idno type="doi">10.7705/biomedica.5478</idno>
<idno type="pmc">PMC7676841</idno>
<idno type="wicri:Area/Main/Corpus">000889</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000889</idno>
<idno type="wicri:Area/Main/Curation">000889</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000889</idno>
<idno type="wicri:Area/Main/Exploration">000889</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Chloroquine and its derivatives in the management of COVID-19: A scoping review</title>
<author><name sortKey="Pimentel, Juan" sort="Pimentel, Juan" uniqKey="Pimentel J" first="Juan" last="Pimentel">Juan Pimentel</name>
<affiliation wicri:level="4"><nlm:affiliation>Community Information and Epidemiological Technologies - Participatory Research at McGill, CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Canada; Facultad de Medicina, Universidad de La Sabana, Chía, Colombia; Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, D.C., Colombia. juan.pimentel@mail.mcgill.ca.</nlm:affiliation>
<country xml:lang="fr">Colombie</country>
<wicri:regionArea>Community Information and Epidemiological Technologies - Participatory Research at McGill, CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Canada; Facultad de Medicina, Universidad de La Sabana, Chía, Colombia; Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, D.C.</wicri:regionArea>
<orgName type="university">Université McGill</orgName>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Andersson, Neil" sort="Andersson, Neil" uniqKey="Andersson N" first="Neil" last="Andersson">Neil Andersson</name>
<affiliation wicri:level="4"><nlm:affiliation>Community Information and Epidemiological Technologies - Participatory Research at McGill, CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Canada; Centro de Investigación de Enfermedades Tropicales, Universidad Autónoma de Guerrero, Acapulco, México. neil.andersson@mcgill.ca.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Mexique</country>
<wicri:regionArea>Community Information and Epidemiological Technologies - Participatory Research at McGill, CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Canada; Centro de Investigación de Enfermedades Tropicales, Universidad Autónoma de Guerrero, Acapulco</wicri:regionArea>
<orgName type="university">Université McGill</orgName>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Biomedica : revista del Instituto Nacional de Salud</title>
<idno type="eISSN">2590-7379</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (physiology)</term>
<term>COVID-19 (MeSH)</term>
<term>Chloroquine (adverse effects)</term>
<term>Chloroquine (pharmacology)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Clinical Trials as Topic (MeSH)</term>
<term>Compassionate Use Trials (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Cytokine Release Syndrome (drug therapy)</term>
<term>Drug Repositioning (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Hydroxychloroquine (pharmacology)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Multicenter Studies as Topic (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Randomized Controlled Trials as Topic (MeSH)</term>
<term>Registries (MeSH)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (effets indésirables)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (physiologie)</term>
<term>Chloroquine (effets indésirables)</term>
<term>Chloroquine (pharmacologie)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Enregistrements (MeSH)</term>
<term>Essais cliniques comme sujet (MeSH)</term>
<term>Essais cliniques à usage compassionnel (MeSH)</term>
<term>Essais contrôlés randomisés comme sujet (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Hydroxychloroquine (pharmacologie)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Repositionnement des médicaments (MeSH)</term>
<term>Réplication virale (effets des médicaments et des substances chimiques)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Études multicentriques comme sujet (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
<term>Réplication virale</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Clinical Trials as Topic</term>
<term>Compassionate Use Trials</term>
<term>Drug Repositioning</term>
<term>Humans</term>
<term>Multicenter Studies as Topic</term>
<term>Pandemics</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Registries</term>
<term>SARS-CoV-2</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Enregistrements</term>
<term>Essais cliniques comme sujet</term>
<term>Essais cliniques à usage compassionnel</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Repositionnement des médicaments</term>
<term>Résultat thérapeutique</term>
<term>Études multicentriques comme sujet</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Introduction: Recently, researchers from China and France reported on the effectiveness of chloroquine and hydroxychloroquine for the inhibition of SARS-CoV-2 viral replication in vitro. Timely dissemination of scientific information is key in times of pandemic. A systematic review of the effect and safety of these drugs on COVID-19 is urgently needed.
Objective: To map published studies until March 25, 2020, on the use of chloroquine and its derivates in patients with COVID-19.
Materials and methods: We searched on PubMed, Embase, Lilacs, and 15 registries from the World Health Organization’s International Clinical Trials Registry Platform for theoretical and empirical research in English, Spanish, Italian, French, or Portuguese until March 25, 2020, and made a narrative synthesis of the results.
Results: We included 19 records and 24 trial registries (n=43) including 18,059 patients. China registered 66% (16/24) of the trials. Nine trials evaluate chloroquine exclusively and eight hydroxychloroquine. The records are comments (n=9), in vitro studies (n=3), narrative reviews (n=2), clinical guidelines (n=2), as well as a systematic review, an expert consensus, and a clinical trial.
Conclusions: One small (n=26), non-randomized, and flawed clinical trial supports hydroxychloroquine use in patients with COVID-19. There is an urgent need for more clinical trial results to determine the effect and safety of chloroquine and hydroxychloroquine on COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33152192</PMID>
<DateCompleted><Year>2020</Year>
<Month>11</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2590-7379</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>40</Volume>
<Issue>Supl. 2</Issue>
<PubDate><Year>2020</Year>
<Month>10</Month>
<Day>30</Day>
</PubDate>
</JournalIssue>
<Title>Biomedica : revista del Instituto Nacional de Salud</Title>
<ISOAbbreviation>Biomedica</ISOAbbreviation>
</Journal>
<ArticleTitle>Chloroquine and its derivatives in the management of COVID-19: A scoping review</ArticleTitle>
<Pagination><MedlinePgn>80-95</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.7705/biomedica.5478</ELocationID>
<Abstract><AbstractText>Introduction: Recently, researchers from China and France reported on the effectiveness of chloroquine and hydroxychloroquine for the inhibition of SARS-CoV-2 viral replication in vitro. Timely dissemination of scientific information is key in times of pandemic. A systematic review of the effect and safety of these drugs on COVID-19 is urgently needed.
Objective: To map published studies until March 25, 2020, on the use of chloroquine and its derivates in patients with COVID-19.
Materials and methods: We searched on PubMed, Embase, Lilacs, and 15 registries from the World Health Organization’s International Clinical Trials Registry Platform for theoretical and empirical research in English, Spanish, Italian, French, or Portuguese until March 25, 2020, and made a narrative synthesis of the results.
Results: We included 19 records and 24 trial registries (n=43) including 18,059 patients. China registered 66% (16/24) of the trials. Nine trials evaluate chloroquine exclusively and eight hydroxychloroquine. The records are comments (n=9), in vitro studies (n=3), narrative reviews (n=2), clinical guidelines (n=2), as well as a systematic review, an expert consensus, and a clinical trial.
Conclusions: One small (n=26), non-randomized, and flawed clinical trial supports hydroxychloroquine use in patients with COVID-19. There is an urgent need for more clinical trial results to determine the effect and safety of chloroquine and hydroxychloroquine on COVID-19.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pimentel</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Community Information and Epidemiological Technologies - Participatory Research at McGill, CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Canada; Facultad de Medicina, Universidad de La Sabana, Chía, Colombia; Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, D.C., Colombia. juan.pimentel@mail.mcgill.ca.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Andersson</LastName>
<ForeName>Neil</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Community Information and Epidemiological Technologies - Participatory Research at McGill, CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Canada; Centro de Investigación de Enfermedades Tropicales, Universidad Autónoma de Guerrero, Acapulco, México. neil.andersson@mcgill.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>spa</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>[Cloroquina y sus derivados en el manejo de la COVID-19: una revisión sistemática exploratoria].</VernacularTitle>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>10</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Colombia</Country>
<MedlineTA>Biomedica</MedlineTA>
<NlmUniqueID>8205605</NlmUniqueID>
<ISSNLinking>0120-4157</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057176" MajorTopicYN="N">Compassionate Use Trials</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherAbstract Type="Publisher" Language="spa"><AbstractText>Introducción. Recientemente, investigadores chinos y franceses reportaron la eficacia de la cloroquina y la hidroxicloroquina para inhibir la replicación in vitro del virus SARS-CoV-2. La diseminación oportuna de la información científica es clave en tiempos de pandemia. Es urgente contar con una revisión sistemática sobre el efecto y la seguridad de estos medicamentos en la COVID-19. Objetivo. Describir el estado actual de la literatura científica publicada hasta el 25 de marzo de 2020 sobre el uso de la cloroquina o sus derivados en el manejo de pacientes con COVID-19. Materiales y métodos. Se hizo una revisión sistemática exploratoria en PubMed, Embase, Lilacs y 15 bases de datos de la Plataforma de Registros Internacionales de Ensayos Clínicos de la Organización Mundial de la Salud (OMS). Se incluyeron publicaciones empíricas y teóricas en inglés, español, italiano, francés o portugués, y se hizo una síntesis narrativa de los resultados. Resultados. Se incluyeron 19 documentos y 24 registros de ensayos clínicos (n=43) de 18.059 pacientes. El 66 % (16/24) de los ensayos están registrados en China. Nueve ensayos evalúan la cloroquina exclusivamente y ocho, la hidroxicloroquina. Los documentos son comentarios (n=9), estudios in vitro (n=3), revisiones narrativas (n=2), guías de práctica clínica (n=2), así como una revisión sistemática, un consenso de expertos y un ensayo controlado. Conclusiones. Un ensayo clínico pequeño (n=26), no aleatorizado y defectuoso, respalda el uso de la hidroxicloroquina en pacientes con COVID-19. Se requiere de manera urgente tener acceso a los resultados de otros ensayos clínicos para determinar la efectividad y la seguridad de la cloroquina y sus derivados en pacientes con COVID-19.</AbstractText>
</OtherAbstract>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">chloroquine</Keyword>
<Keyword MajorTopicYN="Y">hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="Y">coronavirus</Keyword>
<Keyword MajorTopicYN="Y">systematic review</Keyword>
<Keyword MajorTopicYN="Y">clinical trial</Keyword>
<Keyword MajorTopicYN="Y">pandemics</Keyword>
<Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>11</Month>
<Day>5</Day>
<Hour>17</Hour>
<Minute>15</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>11</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33152192</ArticleId>
<ArticleId IdType="doi">10.7705/biomedica.5478</ArticleId>
<ArticleId IdType="pmc">PMC7676841</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2014 Mar;58(5):683-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24319085</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2007 Oct;30(4):297-308</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17629679</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Med Res Methodol. 2007 Feb 15;7:10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17302989</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Mar;55(3):105923</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32070753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Implement Sci. 2010 Sep 20;5:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20854677</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AIDS Patient Care STDS. 2018 Apr;32(4):129-148</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29630850</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 May;177:104762</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32147496</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 29;395(10225):683-684</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32122468</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Evid Based Healthc. 2015 Sep;13(3):141-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26134548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2018 Oct 2;169(7):467-473</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30178033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19506054</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Games Health J. 2020 Jun;9(3):164-181</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32027184</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Syst Rev. 2016 Dec 5;5(1):210</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27919275</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ Open. 2016 May 25;6(5):e011869</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27225653</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Pregnancy Childbirth. 2020 Mar 12;20(1):156</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32164598</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2006 Feb;6(2):67-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16439323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):1-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32092748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Public Health. 2017 May 30;17(Suppl 1):384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28699552</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Colombie</li>
<li>Mexique</li>
</country>
<region><li>Québec</li>
</region>
<settlement><li>Montréal</li>
</settlement>
<orgName><li>Université McGill</li>
</orgName>
</list>
<tree><country name="Colombie"><region name="Québec"><name sortKey="Pimentel, Juan" sort="Pimentel, Juan" uniqKey="Pimentel J" first="Juan" last="Pimentel">Juan Pimentel</name>
</region>
</country>
<country name="Mexique"><region name="Québec"><name sortKey="Andersson, Neil" sort="Andersson, Neil" uniqKey="Andersson N" first="Neil" last="Andersson">Neil Andersson</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001612 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001612 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33152192
   |texte=   Chloroquine and its derivatives in the management of COVID-19: A scoping review
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33152192" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Chloroquine and its derivatives in the management of COVID-19: A scoping review

Chloroquine and its derivatives in the management of COVID-19: A scoping review

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki